3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Phase 2
1
Status
Recruiting
2
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Conditions
Breast Neoplasms
369
Carcinoma, Non-Small-Cell Lung
315
Neoplasms
289
Prostatic Neoplasms
245
Colorectal Neoplasms
214
Multiple Myeloma
182
Lung Neoplasms
170
Neoplasm Metastasis
152
Leukemia, Myeloid, Acute
137
Pancreatic Neoplasms
130
Squamous Cell Carcinoma of Head and Neck
127
Ovarian Neoplasms
117
Melanoma
98
Carcinoma, Renal Cell
94
Recurrence
87
Stomach Neoplasms
81
Precursor Cell Lymphoblastic Leukemia-Lymphoma
80
Carcinoma, Hepatocellular
80
Lymphoma, Non-Hodgkin
79
Head and Neck Neoplasms
79
Lymphoma
78
Glioblastoma
78
Triple Negative Breast Neoplasms
76
Lymphoma, Large B-Cell, Diffuse
75
Urinary Bladder Neoplasms
69
Endometrial Neoplasms
68
Brain Neoplasms
68
Leukemia, Lymphocytic, Chronic, B-Cell
65
Uterine Cervical Neoplasms
62
Lymphoma, Follicular
62
Interventions
Alpelisib
2
mirdametinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Interventional
×
Lymphangioma
×
30 days
×
Clear all
NCT05948943
2026-05-12
EPIK-L1
Novartis
Phase 2/3
Recruiting
232 enrolled
NCT05983159
2026-05-05
TARGET-VM
Murdoch Childrens Research Institute
Phase 2
Recruiting
50 enrolled